313 related articles for article (PubMed ID: 9336134)
1. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104.
Murray KJ; Scott C; Greenberg HM; Emami B; Seider M; Vora NL; Olson C; Whitton A; Movsas B; Curran W
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):571-4. PubMed ID: 9336134
[TBL] [Abstract][Full Text] [Related]
2. Importance of the mini-mental status examination in the treatment of patients with brain metastases: a report from the Radiation Therapy Oncology Group protocol 91-04.
Murray KJ; Scott C; Zachariah B; Michalski JM; Demas W; Vora NL; Whitton A; Movsas B
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):59-64. PubMed ID: 10924972
[TBL] [Abstract][Full Text] [Related]
3. Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs. accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91-04.
Regine WF; Scott C; Murray K; Curran W
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):711-7. PubMed ID: 11597813
[TBL] [Abstract][Full Text] [Related]
4. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases.
Gaspar LE; Scott C; Murray K; Curran W
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):1001-6. PubMed ID: 10863071
[TBL] [Abstract][Full Text] [Related]
5. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
6. Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of Radiation Therapy Oncology Group 85-28.
Epstein BE; Scott CB; Sause WT; Rotman M; Sneed PK; Janjan NA; Davis LW; Selim H; Mohiuddin M; Wasserman TH
Cancer; 1993 Feb; 71(4):1362-7. PubMed ID: 8435812
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?
Nieder C; Nestle U; Motaref B; Walter K; Niewald M; Schnabel K
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):297-302. PubMed ID: 10661335
[TBL] [Abstract][Full Text] [Related]
8. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.
Fu KK; Pajak TF; Trotti A; Jones CU; Spencer SA; Phillips TL; Garden AS; Ridge JA; Cooper JS; Ang KK
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):7-16. PubMed ID: 10924966
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
[TBL] [Abstract][Full Text] [Related]
10. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.
Murray KJ; Nelson DF; Scott C; Fischbach AJ; Porter A; Farnan N; Curran WJ
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):453-9. PubMed ID: 7852106
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of short-course accelerated whole brain radiation therapy for multiple brain metastases.
Caravatta L; Deodato F; Ferro M; Macchia G; Massaccesi M; Cilla S; Padula GD; Mignogna S; Tambaro R; Carrozza F; Flocco M; Cantore G; Scapati A; Buwenge M; Sticca G; Valentini V; Cellini N; Morganti AG
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e463-8. PubMed ID: 22909415
[TBL] [Abstract][Full Text] [Related]
12. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Werner-Wasik M; Scott CB; Nelson DF; Gaspar LE; Murray KJ; Fischbach JA; Nelson JS; Weinstein AS; Curran WJ
Cancer; 1996 Apr; 77(8):1535-43. PubMed ID: 8608540
[TBL] [Abstract][Full Text] [Related]
13. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
Coughlin C; Scott C; Langer C; Coia L; Curran W; Rubin P
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1351-8. PubMed ID: 11121633
[TBL] [Abstract][Full Text] [Related]
14. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial.
Olmi P; Crispino S; Fallai C; Torri V; Rossi F; Bolner A; Amichetti M; Signor M; Taino R; Squadrelli M; Colombo A; Ardizzoia A; Ponticelli P; Franchin G; Minatel E; Gobitti C; Atzeni G; Gava A; Flann M; Marsoni S
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):78-92. PubMed ID: 12504039
[TBL] [Abstract][Full Text] [Related]
15. Recursive partitioning analysis (RPA) class does not predict survival in patients with four or more brain metastases.
Nieder C; Andratschke N; Grosu AL; Molls M
Strahlenther Onkol; 2003 Jan; 179(1):16-20. PubMed ID: 12540980
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of accelerated fractionation in brain metastases RTOG 85-28.
Sause WT; Scott C; Krisch R; Rotman M; Sneed PK; Janjan N; Davis L; Curran W; Choi KN; Selim H
Int J Radiat Oncol Biol Phys; 1993 Jul; 26(4):653-7. PubMed ID: 8330997
[TBL] [Abstract][Full Text] [Related]
17. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy.
Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hoerner-Rieber J; König L; Kappes J; Thomas M; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
J Neurooncol; 2017 Aug; 134(1):205-212. PubMed ID: 28560661
[TBL] [Abstract][Full Text] [Related]
18. A boost in addition to whole-brain radiotherapy improves patient outcome after resection of 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients.
Rades D; Pluemer A; Veninga T; Dunst J; Schild SE
Cancer; 2007 Oct; 110(7):1551-9. PubMed ID: 17654659
[TBL] [Abstract][Full Text] [Related]
19. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
Ali AN; Zhang P; Yung WKA; Chen Y; Movsas B; Urtasun RC; Jones CU; Choi KN; Michalski JM; Fischbach AJ; Markoe AM; Schultz CJ; Penas-Prado M; Garg MK; Hartford AC; Kim HE; Won M; Curran WJ
J Neurooncol; 2018 Mar; 137(1):39-47. PubMed ID: 29404979
[TBL] [Abstract][Full Text] [Related]
20. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database.
Shaw E; Scott C; Suh J; Kadish S; Stea B; Hackman J; Pearlman A; Murray K; Gaspar L; Mehta M; Curran W; Gerber M
J Clin Oncol; 2003 Jun; 21(12):2364-71. PubMed ID: 12805339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
